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Summary 
A panel of DBA/2 T  cell hybridomas specific for the sperm whale myoglobin epitope 110-121 
was found to recognize antigen presented by the mixed isotype class II molecule EczdAfl  a. The 
response was blocked by monodonal  antibodies  specific  for Ec~ and A/3  a chains;  in addition, 
the hybridomas responded to antigen  presented by L  cells expressing Ec~A~ a molecules,  and 
made  no  response  with  L  cells  expressing  I-A  a  or  I-E  d  molecules.  Two  more  groups  of 
hybridomas isolated from DBA/2 and B10.D2 mice immunized with myoglobin also recognized 
peptide  110-121 presented  by  Ec~aA/3  d.  Thus,  although  it  is  expressed  at  biochemically 
undetectable levels on spleen cells, the E&A/3 a molecule is an important presenting dement in 
normal H-2  d mice making a conventional immune response to a protein antigen.  These results 
suggest  that  high levds of class  II expression are not  a prerequisite  for T  cell activation. 
C 
lass II MHC-encoded molecules are heterodimeric mem- 
brane proteins that bind peptides and display them on 
the cell surface for recognition by T lymphocytes. The c~ and 
chains of class II MHC molecules show very strong prefer- 
ences for matched isotypic pairing (1, 2). High level expres- 
sion of mixed isotype molecules can be achieved after trans- 
fection of certain combinations of c~ and/3  gene pairs  into 
L cells (3-5). There is also biochemical, serological, and func- 
tional evidence for low-level expression on some B cell tumors 
(4, 6) and human EBV-transformed cells (7). EozAB mole- 
cules can be detected on the spleen ceils of mouse strains with 
defective E~ expression (8), and also in mice expressing high 
levels of an Ec~ transgene (8-10,) where they can be recog- 
nized both as alloantigens (9) and as antigen-presenting mol- 
ecules (10).  Despite these latter results, it was thought  that 
mixed isotype molecules were expressed at levds too low to 
play any physiological role in individuals with balanced class 
II chain expression.  Here we show that  the biochemically 
undetectable mixed isotype molecule Eo~dA/~  d constitutes a 
major presenting dement in H-2  a mice for a determinant on 
sperm  whale  myoglobin  (SpW  Mb). 1  The  quantitative 
aspects of this mixed isotype molecule suggest that the very 
low number of MHC molecules expressed is not limiting 
s Abbn,  t,  iatious used in this patxor: LCB, long chain biotinylated; SpW Mb, 
sperm whale myoglobin. 
in T  cell activation,  and may have important  implications 
for understanding  certain  autoimmune  states. 
Materials  and Methods 
Animals.  DBA/2 mice were obtained from The Jackson Labo- 
ratory (Bar Harbor,  ME) or from the National  Cancer Institute 
(Bethesda, MD). Males, 8-12 wk of age, were used for all ex- 
periments. 
Antigens.  SpW Mb was purchased  from Serva (Heidelberg, 
Germany). SpW Mb peptides and 110-121 SpW Mb long chain bio- 
tinylated  (LCB) peptide  at the NHz terminus  were synthesized 
using standard solid phase methods as previously described (11). 
Antigen-presenting Cells.  The L cell transfectants RT 7.7H7 14.3 
(EclAt) (3), RT 10.3 C1 (EcxE3  a) (3), RT 2.3.3H D6 (AozdAB  a) 
(12), and CA36.2.1.Ii (Eo~E3 a and invariant chain) (13), and the 
A20 B cell lymphoma line (14) have been previously described. APC 
were exposed to 3,000 tad from a cesium source before coculture 
with T cells. 
T Cell Hfiridomas.  The T cell hybridomas in Table 1, A and 
D were obtained by fusion of SpW Mb-specific T cell clones (15, 
16) with the BW5147 TCR-cd3- cell line (17) as previously de- 
scribed (18). Briefly, 3 d before fusion, the T cell clones were re- 
stimulated as previously described (16) in the presence of 5 U/ml 
of human rlL-2 (Cetus Corp.,  Emeryville, CA). After removal of 
dead cells on a Ficoll-Paque gradient,  2-10  x  106 cells were fused 
with 40  x  106 BW5147 cells as described (18). The antigen fine 
specificity of the T cell hybridomas was indistinguishable from that 
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B and C were produced by fusion ofSpW Mb-immune lymph node 
cells stimulated once in vitro and will be reported elsewhere (K. 
SeUins et al., manuscript  in preparation). 
11.2 Assays.  0.1-1  x  10  s hybridoma cells and 0.5-1  x  10  s ir- 
radiated APC were cultured with serial dilutions of antigen in flat- 
bottomed microtiter weUs. After a 24-h incubation at 37~  100 
#1 supernatant was harvested from each well, frozen, thawed, and 
added to 0.5-1.0  x  104 HT-2 cells in 100 #1 medium to measure 
IL-2 production as Previously described (18). Plates were pulsed with 
[3H]TdR (1/~Ci/well)  at 20 h, and harvested at 24 h. Results are 
given as the mean of triplicate wells  •  SD. 
Antibody Blocking.  A20  APC  (10S/well) were  incubated  at 
room temperature for 30 rain with serial twofold dilutions of mAb. 
104 hybridoma cells/well and antigen  were then  added, and the 
plates incubated for 24 h at 37~  100/zl supernatant  was har- 
vested from each well and assayed for IL-2 as described above. 
Peptide Binding Assays.  Binding assays with SpW Mb 110-121 
LCB peptide were ix-rformed as previously described (11, 19). Briefly, 
class II MHC-negative cells; DAP3; Ec~E~, A~At3  a, and Ec~AB  a 
L cell transfectants (3  x  10  s) were incubated in Dulbecco's PBS 
containing biotinyhted peptide at different concentrations at 37~ 
for 4 h in 96-well round-bottomed plates. Subsequently, the cells 
were stained with successive layers of fluoresceinated avidin D (10 
/zg/ml in PBS/0.1% BSA; Vector Laboratories, Burlingame, CA), 
biotinylated  anti-avidin  D (10 #g/ml in PBS/0.1%  BSA; Vector 
Laboratories), and again fluoresceinated avidin D, each for 30 rain 
at 4~  The mean fluorescence of 5,000 stained cells was deter- 
mined by flow cytometry on a FACScan  |  analyzer (Becton Dick- 
inson Immunochemistry Systems, Mountain View, CA). The back- 
ground, measured in the absence of peptide, as well as nonspecific 
binding signal to a class II MHC-negative fibroblast cell line, DAP3, 
was subtracted  from each signal. 
Results and Discussion 
Analysis of a panel of DBA/2 (H-2  d) SpW Mb-specific T 
cell clones (20) originally suggested that six independent dones 
recognized the determinant  110-121 when presented by the 
EotaE/$  a  class  II  molecule.  First,  the  response  could  be 
blocked by the E~-specific mAb 14.4.4S,  and was apparently 
unaffected  by  the  ABa-spedfic antibody  MKD6.  Second, 
there was no response to antigen presented by D2.GD spleen 
ceils;  the D2.GD strain has functional A~ a, Aot a, and E~  a 
genes, but carries a defective Eot allde (21), and is therefore 
ActaA/3 a (I-A)+,  and EtudE/3  d (I-E)-. 
Many of these clones were subsequently fused with the 
TCR-ot//3- BW5147 variant fusion partner (17) to generate 
T cell hybridomas, which were assayed on class II-expressing 
B cells and L cell transfectants.  The E~xaE/3  a + L cell line CA 
36.2.1Ii,  transfected with  the EodEB  a and  invariant  chain 
genes (13), presented antigen very efficiently to the hybridoma 
13.26.8-H6, spedfic for an epitope within residues 132-147, 
confirming  the EotaE/3  a presentation  of antigen  to T  cells 
specific for this epitope (22). However, CA 36.2.1.Ii cells were 
unable to present myoglobin or peptide to the 110-121-specific 
hybridoma 12.2.9-H7. Both hybridomas made excellent con- 
trol responses to antigen presented by the BALB/c (H-2  a) 
B lymphoma cell line A20 (data not shown). Similar results 
were obtained using several other 110-121-specific hybridomas 
and Ec~aElJa-transfected L cell lines (G. Ruberti, unpublished 
results). 
These experiments suggested that the 110-121-specific hy- 
bridomas did not recognize 110-121 presented by EotaEB  d, 
even though the Eot  a chain dearly formed part of the pre- 
senting  molecule.  Ec~  d chains  expressed  in  H-2  d cells  as- 
sociated preferentially with EB  d chains, but co-transfection 
experiments have shown that Ect~ can pair with AB  a to be 
expressed as an isotype-mismatched class II molecule (2-4). 
Since all our data were consistent with Ec~dABd-associated 
recognition of the 110-121 epitope, the antibody inhibition 
experiments  were repeated using higher concentrations  of 
MKD6 and 14.4.4S.  The specificity of the antibody prepara- 
tions is shown in Fig.  1, A  and B. MKD6 blocked the re- 
sponse of an AotdABa/106-118-spedfic hybridoma (11.12.8b- 
H5.1), but had no effect on the response of the Ec~E/3a/132 - 
147-specific  hybridoma  13.26.8-H6.1.  Conversely,  14.4.4S 
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Figure 1.  mAbs  specific  for A~ d and Ect block the T cell response of 
T cell hybridomas specific for peptide 110-121. T cell hybtidomas were 
stimulated with SpW Mb presented by A20 cells in the presence of serial 
twofold dilutions of the A3a-specific antibody MKD6 (0) or the E~- 
specific  antibody 14.4.4S (O); control wells  contained medium alone (Q) 
or antigen without antibody  (0). Hybridomas  were: (A) 11.12.Sb-H5.1; 
(B) 13.26.8-H6.1; (C) 8.2.1d-Hal.5; (D) 9.4.23.Hlb.2; (E) 11.3.7e-H2.2.3; 
and (F) 12.2.9-H7.2. Those hybridomas are subclones  of those in Fig. 2 
and Table 1. Antigen concentrations, chosen to give slightly suboptimal 
proliferation, were 0.16/zM (B and C), 0.31 #M (A and E), 0.62 #M 
(F), or 1.25 #M (D). Results  are given  as the mean of triplicate wells + SE. 
158  Hybrid  EotaA~3  d Molecule and Myoglobin Response Table  1.  Response  of DBA/2 and BIO.D2 T Cell Hybridomas 
to Peptide 110-121 Presented by E~A~, EotF~, and AoflA~ 
L Cell Transfectants 
Hybridomas  EcxA/~  a  Ec~E~  a  AccaA/~  a 
A  11.3.7e-H2  152,354  274  529 
8.2.1d-H1a  129,437  440  927 
12.2.9-H7  97,202  923  228 
9.4.23-Hlb  141,817  2,456  493 
14.12.21-H10  119,136  2,410  2,425 
14.16.12-H7b  131,807  1,791  2,683 
B  DB10 10.H7  115,140  2,924  1,590 
DB7 2.E2  133,117  1,591  1,339 
DB10 9.C6  84,063  2,751  1,227 
C  B17 9.B4  129,299  2,410  2,324 
B17 9.C9  140,681  1,378  1,234 
B17 9.A10  195,889  722  1,226 
B13 5.G5  133,383  1,910  2,312 
B13 5.D10  82,717  780  210 
B13 5.Cll  123,662  1,386  2,624 
B13 5.B8  141,378  440  927 
B19 4.E8  139,560  960  1,110 
D  13.26.8-H6  2,090  101,170  2,241 
11.12.8b-H5  1,378  1,110  108,768 
(A) 110-121-specitic DBA/2 hybridomas  derived  by fusion  of T cell  clones 
isolated from long-term SpW Mb-specific T cell lines, as previously 
described (15, 16); (/3) 110-121-specitic DBA/2 hybridomas  produced  by 
fusion of SpW Mb-immune  lymph node cells stimulated  once in vitro; 
(C) 110-121-specific B10.D2 hybridomas produced by fusion of SpW 
Mb-immune lymph node cells stimulated once in vitro; (D) control 
responses of the DBA/2 hybridomas  13.26.8-H6 and 11.12.Sb-H5 (15). 
All the hybridomas  in B and C appear to be independent,  as determined 
by TCK V/~ sequence or antigen  fine  specificity.  (A, B, and C) hybrido- 
mas were stimulated  with peptide 110-121 (50 #M); (D) 13.26.8-H6 and 
11.12.Sb-H5 were stimulated  with peptides 132-147 (50/dr  and 102-120 
(50 #M), respectively.  Peptide was presented  by the L cell transfectants 
RT 7.7H7 14.3 (EcxAB  d) 0), KT 10.3 C1 (EotEfl  d) (3), and RT 2.3.3H 
D6  (Ao0A/~  d)  (12). Representative results of four experiments are 
shown. Results are expressed as the mean of triplicate wells in counts 
per minute. The SDs were within 10% of the mean values. 
conditions where conventional Act~Al3a-controlled responses 
were blocked quite efficiently. 
To test directly whether E~aA/3 a could present the 110- 
121 determinant, the hybridomas were assayed  on L cells trans- 
s  with Ac~dAB  a (KT 2.3.3H D6) (12), E~EI3  d (KT 10.3 
C1) (3),  or EcxAfl  a (KT 7.7H7 14.3) (3).  Table 1 A  shows 
that six independent 110-121-specific hybridomas responded 
to peptide  110-121 presented by the EotAl3a-expressing  L 
cells, but were not stimulated by this peptide on Ac~dAB  a 
or EotE/3  a transfectant cells. The control Ac~AB  d (11.12.8b- 
HS)- and EotdE/3  d (13.26.8-H6)-restricted hybridomas were 
stimulated by peptides 102-120 and 132-147 on Ac~dA~  a+ 
and E~EI3  a  + L cells, respectively, but were unable to recog- 
nize peptide presented by Ec~AB  d transfectants (Table 1 D). 
These six DBA/2 110-121-specific hybridomas were made 
from clones isolated from T cell lines stimulated several times 
in vitro before cloning. A second set of hybridomas was made 
from myoglobin-immune DBA/2 lymph node cells stimu- 
lated  just once in vitro before fusion (K. S. Sellins et al., manu- 
script in preparation). Those hybridomas that made no re- 
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completely blocked the response of 13.26.8-H6.1,  but did not 
inhibit the response of 11.12.8b-HS.1. Both antibodies blocked 
the response of four independent 110-121-specific hybridomas, 
8.2.1d-Hla.5, 9.4.23-H1b.2,  11.3.7e-H2.2.3,  and 12.2.9-H7.2 
(Fig.  1,  C-F).  It was essential  to assay antibody blocking 
at limiting antigen concentrations; at higher antigen con- 
centrations, 14.4.4S still blocked the response almost com- 
pletely, whereas MKD6 gave little if any inhibition. It has 
been shown that MKD6 binds poorly to Ec~A/~  a, compared 
with Ac~AB  a (3, 4); this could explain why we previously 
saw no inhibition of the 110-121 response with MKD6, under 
Peptide concentration  (p.M} 
Figure 2.  Comparison  of antigen  presentation  by spleen  cells,  A20 cells, 
and class II MHC-transfected  L cells. T cell hybridomas  were cultured 
with serial  fivefold  dilutions  of peptides 110-121 (A and B), 132-147 (C), 
or 102-120 (D), presented  by DBA/2 spleen  cells (O) A20 (@) or L cells 
(I) expressing  E~xAiSa  (A and B), EaEB  a (C), or AotaA~  a (D); details 
of these L cell lines are given  in the legend  to Table 1. Hybridomas  were: 
(.4) 9.4.23-H1b; (B) 11.3.7e-H2; (C) 13.26.8-H6; and (D) 11.12.Sb-H5. 
Representative  results  are shown  from  three  experiments.  Results  are rep- 
resented as counts per minute. Standard deviations  were within 10% of 
the mean values. Similar  results were obtained  with the 110.121-specific 
bybridomas 8.2.1d-H1a and 14.16.12-H7b (data not shown). 
159  Ruberti  et al. found to recognize antigen presented by EaAB  d, with no 
crossreactive recognition of peptide presented by Ac~dA~  a or 
Ec~E~  d (Table  1  B).  Finally,  110-121-specific hybridomas 
from the H-2  a strain,  B10.D2,  also made after  a single in 
vitro restimulation and unresponsive to antigen presented by 
D2.GD spleen cells (K. S. Sdlins, et al., manuscript in prepa- 
ration), were again found to recognize antigen presented by 
EaA3  a (Table 1 C). Thus, presentation of peptide 110-121 
by the mixed isotype molecule EotaAB  a was a reproducible 
phenomenon that could be observed in two different H-2  a 
mouse strains. 
In normal H-2  d cells,  with balanced expression of the four 
class II chains, it has been estimated that Eo~A3  a molecules 
account for <5% of the class II molecules (2). To test this, 
L cells (AoeaA3  d, Ec~E3  d, or EoeA3  a) expressing MHC mol- 
ecules at levels similar to that on A20 and H-2  a spleen cells 
were compared for their ability to present myoglobin pep- 
tides  to the various  hybridomas. For AotaA~  a- (Fig.  2 D) 
and Ec~aE3  d- (Fig. 2 C) restricted responses, the L cells gave 
dose response curves very similar to those seen with A20 and 
H-2  d spleen cells. In contrast, the EoLA3d-transfected  L cells 
allowed half-maximal responses at peptide concentrations three 
to five orders  of magnitude lower than with A20 or H-2  a 
spleen cells (Fig. 2, A  and B). These results were consistent 
with very low expression of EolaA3  a  relative to Act,  dA~  d and 
EccdE~  d on H-2  a cells, and demonstrated the efficiency of T 
cell  recognition of peptide 110-121 presented by EoeaA3  a 
molecules. 
Given the very low level of Ec~dA3 d expression  on H-2  d 
cells, the repeated isolation of 110-121-specific T  cells that 
recognized the antigen presented by this molecule was rather 
surprising. One possibility was that peptide 110-121 bound 
very  efficiently  to  E~dA~  d,  so  that  the  density  of  110- 
121/Ec~dA3  d complexes on the antigen-presenting cell sur- 
face was high enough to trigger T call activation. Thus, al- 
though Ec~dA~ d expression was low relative to AotdAB  a or 
Ec~dE~  d,  the number of 110-121/Eo~dA~  d complexes could 
have approached that ofpeptides 102-120 and 132-147 bound 
to Ac~dA~ d and EoldA/~  d, respectively. This possibility was 
tested by measuring the mean fluorescent  signals generated 
by the binding of LCB 110-121 peptide to EotE3  a, AoedA3  d, 
and E~A3  a L cell transfectants.  As demonstrated by data 
presented in Fig. 3, this peptide did not bind with detectably 
higher affinity  to the hybrid MHC  molecule than to the 
Ao/dA~  d or EoedE~  d molecules. Another possibility was that 
those T  cells specific for 110-121/EoeaA3  a expressed TCRs 
with high affinity for this ligand. Among the 17 cell lines 
described here, all but one expressed VB8.2; of these,  14/15 
V~8.2 + chains sequenced were V38.2/DB2.1/J32.6, while 
the remaining clone expressed VB8.2/DB2.1/J32.5 (15, 16, 
and K.  S.  Sdlins et  al.,  manuscript in preparation).  The 
V38.2/D32.1/JB2.6 chain can pair with at least four different 
TCR-oe chains to form TCR-oL/3 heterodimers specific for 
110-121/EoldA3  a (16), and it is tempting to speculate  that 
this TCR 3 chain confers particularly high TCR aflinity for 
peptide 110-121 presented by Ec~dA3  a. 
Figure 3.  Mean  fluorescent  signals  generated  by the binding  of LCB 
SpWMb 110-121  peptide  to cells expressing  FaxEB  d (RT 10.3 C1) (ll), 
Ac~dA~  d (RT 2.3.38 06) (ll), and FaxA~  d (RT 7.7H7 14.3) (W) class 
II MHC molecules.  The biotinylated  peptide  was assayed  as described  in 
Materials and Methods. 
There has been considerable debate about any function in 
vivo for mixed isotype class II molecules (2, 23). The crucial 
issue concerns the level of cell surface expression, rather than 
any special properties of mismatched ol/B pairs. Activation 
of class II-specific T cells in the periphery depends critically 
on class II density on the APC (24-26). Mixed isotype class 
II molecules, when expressed at sufficiently high levels, ap- 
pear to have properties indistinguishable from those ofisotype- 
matched molecules. They can be recognized as alloantigens 
(9), present conventional protein antigens (4, 6, 10), and can 
also cause partial deletion of T  cell subsets in Mls-positive 
mice (8). However,  the association  of class II chains is in- 
fluenced by strong isotype and haplotype preferences in o~/B 
pairing (2-4, 27-29),  so that cells with balanced Ac~, AB, 
Eo~, and  E~  chain synthesis express  low or  undetectable 
amounts of mixed isotype molecules. In previous reports, 
mixed isotype molecules have been recognized by T cells only 
when their expression is favored by co-transfection of partic- 
ular dass II ol or ~  chains (4), by unbalanced synthesis of 
the isotypically matched c~ or ~  chain (6-8),  or by the in- 
troduction of Eot transgenes expressed at high levels (8-10). 
The present study shows that normal mice with balanced 
class II c~ and B chain synthesis can use isotypically mismatched 
molecules in a conventional immune response, even though 
these molecules are expressed at such low levels, relative to 
the isotypically matched class II molecules, that they can be 
biochemically undetectable on spleen cells (2, and R. Get- 
main, unpublished results).  These results suggest that high 
levels of class II expression are not a prerequisite for T  cell 
activation.  It is not possible to say from these experiments 
whether the low level of class II expression required for acti- 
160  Hybrid  Eo~AB  a Molecule  and Myoglobin  Response vation in the periphery reflects equally low thresholds  for 
positive or negative selection in the thymus; it has been shown 
by others that levels of class II expression too low to stimu- 
late antigen-specific or allogeneic responses nevertheless in- 
duce tolerance to much higher levels of the same class II mol- 
ecule (9,  10, 30). These data raise questions about the role 
that mismatched MHC molecules might  play in a physio- 
logical immune or autoimmune response without the neces- 
sity of invoking any unbalanced expression of isotype-matched 
chains (2, 23). Antigen presentation by mixed isotype mole- 
cules may well depend both on the particular  antigen  and 
on the available TCtL repertoire. Presentation by mixed iso- 
type molecules in vivo would greatly increase the repertoire 
of class II-restricted T  cell responses, especially in humans, 
where individuals heterozygous for DR, DQ, and DP alleles 
potentially express a very large number of different dass II 
molecules. Certain autoimmune diseases  correlate with ex- 
tended HLA-D haplotypes, rather than with particular DR, 
DQ, or DP alleles  (31-33).  Our results support the possi- 
bility that  these diseases  are induced or maintained  by re- 
sponses involving mixed isotype molecules (23). 
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